Trial Profile
Effects of Dietary and Behavioral Intervention and Orlistat for Management of Obesity and Metabolic Syndrome on Response to Hepatitis C Therapy.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 15 Nov 2018
Price :
$35
*
At a glance
- Drugs Orlistat (Primary) ; Antivirals
- Indications Hepatitis C; Obesity
- Focus Pharmacodynamics; Therapeutic Use
- 21 Mar 2018 Status changed from recruiting to discontinued as Protocol expired and not renewed
- 08 Apr 2009 New trial record